Coeptis Therapeutics (NASDAQ:ZSQR) Posts Quarterly Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) announced its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, Zacks reports. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Coeptis Therapeutics Trading Up 6.9%

Shares of NASDAQ ZSQR traded up $0.27 during mid-day trading on Thursday, hitting $4.16. 398,778 shares of the company traded hands, compared to its average volume of 260,849. Coeptis Therapeutics has a 1 year low of $3.77 and a 1 year high of $21.41. The stock has a market capitalization of $213.95 million, a price-to-earnings ratio of -1.65 and a beta of -0.20. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $8.56 and a two-hundred day moving average of $10.86.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Trading of Coeptis Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in Coeptis Therapeutics during the fourth quarter valued at about $259,000. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after acquiring an additional 2,500 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after acquiring an additional 4,721 shares during the period. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.